Structured evidence table for Alpha Lipoic Acid Blood Glucose Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Alpha Lipoic Acid Blood Glucose Randomized Trial | Experimental data and clinical studies highlight the cardiometabolic changes associated with gonadal aging and reproductive hormones’ withdrawal []. | 3 | Karaflou Maria (2026) | Antioxidants in Menopausal Transition and Male Late-Onset Hypogonadism for the Prevention of Diabetes |
| Alpha Lipoic Acid Blood Glucose Randomized Trial | Body composition changes with increased fat mass and abdominal fat distribution are associated with insulin resistance and subsequent diabetes in older ages [,]. | 3 | Karaflou Maria (2026) | Antioxidants in Menopausal Transition and Male Late-Onset Hypogonadism for the Prevention of Diabetes |
| Alpha Lipoic Acid Blood Glucose Randomized Trial | 5 6 7 Oxidative stress is closely associated with conditions that predispose individuals to T2DM, including obesity. | 3 | Karaflou Maria (2026) | Antioxidants in Menopausal Transition and Male Late-Onset Hypogonadism for the Prevention of Diabetes |
| Alpha Lipoic Acid Blood Glucose Randomized Trial | 1 1 2 www.pubmed.gov Menopause and male late-onset hypogonadism (LOH) are well-described transitions in females and males during their lifespan. | 3 | Karaflou Maria (2026) | Antioxidants in Menopausal Transition and Male Late-Onset Hypogonadism for the Prevention of Diabetes |
| Alpha Lipoic Acid Blood Glucose Randomized Trial | This review critically evaluates the mechanistic rationale and clinical evidence for alpha-lipoic acid (ALA) and benfotiamine as adjunctive treatments for DPN. | 4 | Ciubotaru A (2026) | Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. |
| Alpha Lipoic Acid Blood Glucose Randomized Trial | Evidence was synthesized qualitatively with emphasis on mechanistic plausibility, clinical efficacy, intervention duration, and methodological rigor. | 4 | Ciubotaru A (2026) | Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. |
| Alpha Lipoic Acid Blood Glucose Randomized Trial | The long-term NATHAN 1 trial reported a marginal, borderline significant effect on the primary composite endpoint (NIS-LL, p = 0.05) without significant improvements in nerve conduction studies; therefore, evidence for functional stabilization is very limited and inconclusive. | 4 | Ciubotaru A (2026) | Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. |
| Alpha Lipoic Acid Blood Glucose Randomized Trial | Background Diabetic peripheral neuropathy (DPN) affects up to 50% of diabetes patients and is driven by hyperglycemia-induced oxidative stress, mitochondrial dysfunction, polyol pathway activation, advanced glycation end-product formation, and inflammation. | 4 | Ciubotaru A (2026) | Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. |
Source documents